Dr Lindsay Robertson*
In our recently published work, we studied the impact of the NZ Government preventing new retail outlets from selling tobacco from 2020, while allowing existing retail outlets to continue selling it until they closed or relocated. The estimated outcome would be a 50% decrease in the total number of tobacco retail outlets by 2032. This blog puts these results into the context of tobacco control options for NZ.
Dr Richard Jaine, Dr Giorgi Kvizhinadze, Prof Nick Wilson, Prof Tony Blakely
There is reasonably strong evidence screening for lung cancer with low-dose computed tomography (LDCT) scans is effective at reducing lung cancer mortality. However, new research suggests it is highly unlikely to be cost-effective in NZ. We have just published the first NZ study to examine the cost-effectiveness of lung cancer screening in the journal Lung Cancer, and we estimate that it would cost NZ$154,000 per quality-adjusted life-year (QALY) gained – even among heavy smokers . This means that gaining the equivalent of one year of life in perfect health from lung cancer screening comes with a price tag of about $150,000. This suggests that if we want to reduce the burden of lung cancer in NZ but still have to work within a finite health budget, we should consider more cost-effective means (e.g. enhanced tobacco control).